Managing viral safety deviations in contract manufacturing and CDMO networks Managing Viral Safety Deviations in Contract Manufacturing and CDMO Networks Context Viral safety is a critical aspect of biological product development and manufacturing. The potential for viral contamination necessitates stringent controls throughout the production process, especially in Contract Development and Manufacturing Organizations (CDMOs) that handle the production of biological drugs. Deviations in viral safety protocols may lead to atypical viral clearance results, which pose significant regulatory challenges and patient safety risks. Understanding how to effectively investigate viral safety deviations, implement Corrective and Preventive Actions (CAPA), and maintain compliance with regulatory…

Digital workflows for viral safety deviation management and CAPA tracking Digital workflows for viral safety deviation management and CAPA tracking In today’s pharmaceutical landscape, ensuring viral safety is paramount, particularly as it pertains to biopharmaceutical products. A thorough understanding of viral clearance and the management of deviations is essential for regulatory compliance and product safety. This article explores regulatory affairs surrounding viral safety deviation investigations, atypical results, and Corrective and Preventive Actions (CAPA), emphasizing the role of digital workflows in managing these processes. Context Viral clearance studies are vital for demonstrating the safety of biologics. Regulatory authorities, including the FDA,…